News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VIVUS, Inc. (VVUS) Says Drug Delayed Progression to Diabetes


10/10/2013 7:15:25 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Drugmaker Vivus said patients who took its weight loss drug Qsymia were more than 70 percent less likely to develop type 2 diabetes compared to patients who took a placebo. The data comes from a group of patients who participated in a late-stage clinical trial of Qsymia. Those patients were at high risk for developing diabetes: they had prediabetes or a group of symptoms called metabolic syndrome, which includes high blood pressure, large waist size, and inability to handle glucose.

Help employers find you! Check out all the jobs and post your resume.

Read at BusinessWeek
Read at News Release


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES